Literature DB >> 2440570

Azacitidine: 10 years later.

A B Glover, B R Leyland-Jones, H G Chun, B Davies, D F Hoth.   

Abstract

Azacitidine has been undergoing clinical trials for almost 20 years and is internationally considered to have a useful place in the treatment of acute nonlymphocytic leukemia. However, its role in the various combinations for induction, intensification, maintenance, or relapse regimens has not yet been clearly defined. This review outlines the last 10 years' clinical experience with the drug in acute nonlymphocytic leukemia, analyzes what critical information has yet to be obtained, and suggests what phase III trials may still be feasible to gather that information.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2440570

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  19 in total

1.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements.

Authors:  Allen S Yang; Marcos R H Estécio; Ketan Doshi; Yutaka Kondo; Eloiza H Tajara; Jean-Pierre J Issa
Journal:  Nucleic Acids Res       Date:  2004-02-18       Impact factor: 16.971

2.  Importance of the tmRNA system for cell survival when transcription is blocked by DNA-protein cross-links.

Authors:  H Kenny Kuo; Rachel Krasich; Ashok S Bhagwat; Kenneth N Kreuzer
Journal:  Mol Microbiol       Date:  2010-09-16       Impact factor: 3.501

Review 3.  Epigenetic therapy of leukemia: An update.

Authors:  Nitin Jain; Adriana Rossi; Guillermo Garcia-Manero
Journal:  Int J Biochem Cell Biol       Date:  2008-10-17       Impact factor: 5.085

Review 4.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

5.  HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.

Authors:  Matko Kalac; Luigi Scotto; Enrica Marchi; Jennifer Amengual; Venkatraman E Seshan; Govind Bhagat; Netha Ulahannan; Violetta V Leshchenko; Alexis M Temkin; Samir Parekh; Benjamin Tycko; Owen A O'Connor
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

6.  H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance.

Authors:  Amy V Paschall; Dafeng Yang; Chunwan Lu; Jeong-Hyeon Choi; Xia Li; Feiyan Liu; Mario Figueroa; Nicholas H Oberlies; Cedric Pearce; Wendy B Bollag; Asha Nayak-Kapoor; Kebin Liu
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

7.  IFNγ Induces DNA Methylation-Silenced GPR109A Expression via pSTAT1/p300 and H3K18 Acetylation in Colon Cancer.

Authors:  Kankana Bardhan; Amy V Paschall; Dafeng Yang; May R Chen; Priscilla S Simon; Yangzom D Bhutia; Pamela M Martin; Muthusamy Thangaraju; Darren D Browning; Vadivel Ganapathy; Christopher M Heaton; Keni Gu; Jeffrey R Lee; Kebin Liu
Journal:  Cancer Immunol Res       Date:  2015-03-03       Impact factor: 11.151

8.  Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo.

Authors:  Dafeng Yang; Christina M Torres; Kankana Bardhan; Mary Zimmerman; Tracy L McGaha; Kebin Liu
Journal:  J Immunol       Date:  2012-03-28       Impact factor: 5.422

9.  Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.

Authors:  C P Steuber; T Holbrook; B Camitta; V J Land; C Sexauer; J Krischer
Journal:  Invest New Drugs       Date:  1991-05       Impact factor: 3.850

10.  Azacitidine in the management of patients with myelodysplastic syndromes.

Authors:  Cyrus Khan; Neeta Pathe; Salman Fazal; John Lister; James M Rossetti
Journal:  Ther Adv Hematol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.